[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet",
    "summary": "Read the latest analysis on Vertex stock and its recent earnings report here.",
    "url": "https://finnhub.io/api/news?id=457a1ccd7b4be1b5d342bea5428a17588b135225edd16dc75e6355592dcbb4c3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755009259,
      "headline": "Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet",
      "id": 136321094,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148319783/image_2148319783.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Read the latest analysis on Vertex stock and its recent earnings report here.",
      "url": "https://finnhub.io/api/news?id=457a1ccd7b4be1b5d342bea5428a17588b135225edd16dc75e6355592dcbb4c3"
    }
  },
  {
    "ts": null,
    "headline": "Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise",
    "summary": "Biotechs are coming to the island as tariffs threaten overseas drug exports, and finding Puerto Rico is more than just a leading manufacturing hub.",
    "url": "https://finnhub.io/api/news?id=18e0825ddcf3a73b36aaf4db3edfe28c1dc6e27844d9a3c8b70ef5ce0c7c83b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754981858,
      "headline": "Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise",
      "id": 136315977,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Biotechs are coming to the island as tariffs threaten overseas drug exports, and finding Puerto Rico is more than just a leading manufacturing hub.",
      "url": "https://finnhub.io/api/news?id=18e0825ddcf3a73b36aaf4db3edfe28c1dc6e27844d9a3c8b70ef5ce0c7c83b0"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Announces Bemarituzumab’s Successful Phase 3 Results in FGFR2b+ Gastric Cancer",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Amgen Inc. (NASDAQ:AMGN) reported that the Phase 3 FORTITUDE-101 trial achieved its primary endpoint. It proved a clinically meaningful and statistically significant improvement in overall survival for patients with FGFR2b-overexpressing, metastatic, or unresectable gastric/gastroesophageal junction cancer treated with bemarituzumab […]",
    "url": "https://finnhub.io/api/news?id=df9f9c774b34ac2f805e04ee51728a4e179b450cd9943d3ca3e3141707a943b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754958005,
      "headline": "Amgen Announces Bemarituzumab’s Successful Phase 3 Results in FGFR2b+ Gastric Cancer",
      "id": 136316164,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Amgen Inc. (NASDAQ:AMGN) reported that the Phase 3 FORTITUDE-101 trial achieved its primary endpoint. It proved a clinically meaningful and statistically significant improvement in overall survival for patients with FGFR2b-overexpressing, metastatic, or unresectable gastric/gastroesophageal junction cancer treated with bemarituzumab […]",
      "url": "https://finnhub.io/api/news?id=df9f9c774b34ac2f805e04ee51728a4e179b450cd9943d3ca3e3141707a943b2"
    }
  }
]